Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review
This overview investigates the increasing prevalence of sodium-glucose cotransporter-2 (SGLT-2) inhibitor-associated euglycemic diabetic ketoacidosis (EDKA) in type II diabetes patients. Due to its tendency to occur with normal or somewhat high blood sugar levels, EDKA poses unique obstacles to diagnosis and treatment. Based on an extensive review of recent literature, we examine clinical motifs, hazards, and remedy approaches. Our results emphasize how crucial it is to educate patients and actively monitor their ketone levels, particularly before and after operations or sickness. Our goal is to gain a greater awareness of the intricacies of EDKA in order to guide future investigations in this field and boost therapeutic results and evaluation.
-
DKA, Euglycemic Diabetic Ketoacidosis (EDKA), SGLT-2 Inhibitors, Type II Diabetes, Patient Education
-
(1) Muhammad Adnan
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(2) Ejaz Ahmed
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(3) Aimen Sahar
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(4) Savera Saghir
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(5) Mohammad Hossein Rafieikia
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(6) Ahtasham Saleem
Graduate, Bioscience Department, COMSATS University Islamabad, Pakistan.
Cite this article
-
APA : Adnan, M., Ahmed, E., & Sahar, A. (2024). Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review. Global Pharmaceutical Sciences Review, IX(II), 30-38. https://doi.org/10.31703/gpsr.2024(IX-II).04
-
CHICAGO : Adnan, Muhammad, Ejaz Ahmed, and Aimen Sahar. 2024. "Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review." Global Pharmaceutical Sciences Review, IX (II): 30-38 doi: 10.31703/gpsr.2024(IX-II).04
-
HARVARD : ADNAN, M., AHMED, E. & SAHAR, A. 2024. Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review. Global Pharmaceutical Sciences Review, IX, 30-38.
-
MHRA : Adnan, Muhammad, Ejaz Ahmed, and Aimen Sahar. 2024. "Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review." Global Pharmaceutical Sciences Review, IX: 30-38
-
MLA : Adnan, Muhammad, Ejaz Ahmed, and Aimen Sahar. "Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review." Global Pharmaceutical Sciences Review, IX.II (2024): 30-38 Print.
-
OXFORD : Adnan, Muhammad, Ahmed, Ejaz, and Sahar, Aimen (2024), "Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review", Global Pharmaceutical Sciences Review, IX (II), 30-38
-
TURABIAN : Adnan, Muhammad, Ejaz Ahmed, and Aimen Sahar. "Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhibitors: A Comprehensive Review." Global Pharmaceutical Sciences Review IX, no. II (2024): 30-38. https://doi.org/10.31703/gpsr.2024(IX-II).04